PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Arteriovenous malformation

Drugs in development · updated 30 October 2026

Arteriovenous malformation: drugs in development

As of 30 October 2026 there are 4 active clinical trials (recruiting or ongoing, phases I–III) on 5 drugs for arteriovenous malformation. One is experimental, that is not yet approved in the United States.

4Active trials
1Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ATV-1601I–II1NCT07601425

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
AlpelisibBYL719, Vijoice®II1NCT05983159
EverolimusRAD001, EveroliumusII1NCT07477548
MirdametinibGomekli®, Ezmekly®II1NCT05983159
SirolimusRapamycin, Scomara®II1NCT02042326

Sorted by most advanced phase and number of active trials.

All 5 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001165 “Arteriovenous Malformations”.

ItalianoFrançaisDeutsch